News | Prostate Cancer | August 21, 2015

PET Imaging Detects Fast-Growing Prostate Cancer

PSMA-based PET to distinguish benign prostate lesions and prostate cancer

18F-DCFBC PET/CT

August 21, 2015 — A molecular imaging biomarker is able to detect fast-growing primary prostate cancer and distinguish it from benign prostate lesions, addressing an unmet clinical need. The new research, published in the July 2015 issue of The Journal of Nuclear Medicine, is significant for patients with suspected prostate cancer that has not been confirmed by standard biopsy.

“We were able to demonstrate in our research that PSMA positron emission tomography (PET) imaging was more specific than magnetic resonance imaging (MRI) for detection of clinically significant high-grade prostate cancer lesions, and importantly was able to distinguish benign prostate lesions from primary prostate cancer, currently a difficult diagnostic imaging task,” stated Steven P. Rowe, M.D., Ph.D., resident at Johns Hopkins Medical Institutions in Baltimore, Md. “Additionally, this work demonstrated a direct correlation between PSMA PET radiotracer activity in prostate cancer and prostate adenocarcinoma aggressiveness (Gleason score).” 

The study enrolled 13 patients with primary prostate cancer who were imaged with fluorine-18 (F-18) DCFBC PET prior to scheduled prostatectomy, with 12 of the patients also undergoing pelvic prostate MR imaging. Prostate F-18 DCFBC PET was correlated with MR imaging and histologic and immunohistochemical analysis on a prostate-segment (12 regions) and dominant-lesion basis. There were no incidental extraprostatic findings on PET suggestive of metastatic disease.

Results showed that MR imaging was more sensitive than F-18-DCFBC PET for detection of primary prostate cancer in a per-segment (sensitivities of 0.17 and 0.39 for PET and MR imaging, respectively) and per-dominant (sensitivities of 0.46 and 0.92 for PET and MR imaging, respectively) lesion analysis. However, F-18 DCFBC PET was more specific than MR imaging by per-segment analysis (specificity of 0.96 and 0.89 for PET and MR imaging for non-stringent analysis and 1.00 versus 0.91 for stringent analysis, respectively) and highly specific for detection of high-grade lesions greater than or equal to 1.1 mL in size (Gleason 8 and 9).

Steve Y. Cho, M.D., associate professor at the University of Wisconsin School of Medicine and Public Health, and senior corresponding author of this study, states that the findings contribute to the importance of PSMA-based PET imaging for detection and characterization of the biology of the prostate cancer.

“There are a number of PSMA-based PET agents currently being introduced into prostate cancer imaging, many with improved signal to background uptake and sensitivity from this earlier first-generation PSMA F-18 DCFBC PET radiotracer, which should further improve the detection of prostate cancer,” he said. “While it is difficult to predict which of the numerous prostate cancer molecular imaging agents being developed will ultimately become clinically adopted, this work, in aggregate with that of other groups, suggests there are important advantages to the PSMA ligands for prostate cancer molecular imaging.”

Aside from skin cancer, prostate cancer is the most prevalent form of cancer among men in the United States, according to 2014 statistics from the American Cancer Society. About 233,000 new cases of prostate cancer are expected to be diagnosed and about 29,480 prostate-cancer related deaths are estimated this year.

Authors of the article F-18 DCFBC PET/CT for PSMA-based Detection and Characterization of Primary Prostate Cancer” include Steven P. Rowe, Kenneth L. Gage, Katarzyna Macura, Amanda Blackford, Daniel Holt, Robert F. Dannals, Martin A. Lodge, Ronnie C. Mease, Martin G. Pomper, and Steve Y. Cho, The Russell H. Morgan Department of Radiology and Radiological Science; Sheila F. Faraj, Toby C. Cornish, Nilda Gonzalez-Roibon, Gunes Guner, Enrico Munari, and George J. Netto, Department of Pathology; and Alan W. Partin, Christian P. Pavlovich, Misop Han, H. Ballentine Carter, and Trinity J. Bivalacqua, The James Buchanan Brady Urological Institute and Department of Urology, Johns Hopkins Medical Institutions, Baltimore, MD. This study was funded through the Prostate Cancer Foundation and RSNA Research and Education Foundation.

For more information: jnm.snmjournals.org.

Related Content

Exact Imaging Becomes UroGPO Imaging Partner
News | Ultrasound Imaging | August 10, 2018
Exact Imaging announced that it has become a UroGPO Imaging Partner, joining the North American urology-specific group...
PET Tracer Identifies Estrogen Receptor Expression Differences in Breast Cancer Patients
News | PET Imaging | August 09, 2018
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the...
Novel PET Imaging Method Could Track and Guide Type 1 Diabetes Therapy
News | PET Imaging | August 03, 2018
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The...
Researchers Trace Parkinson’s Damage in the Heart
News | PET Imaging | July 17, 2018
A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and...
SpaceOAR Hydrogel Now Available in Japan
News | Patient Positioning Radiation Therapy | July 16, 2018
Augmenix K.K. announced that SpaceOAR hydrogel, a soft, implanted absorbable gel spacer is now available to all...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
SNMMI Image of the Year Highlights Theranostic Approach for Advanced Prostate Cancer

IMAGE OF THE YEAR: PSMA PET before and after lutetium-177 PSMA617 theranostics in 8 patients with metastatic prostate cancer who exhausted standard therapeutic options.

68Ga-PSMA11 PET maximum intensity projection (MIP) images at baseline and 3 months after 177Lu-PSMA617 in 8 patients with PSA decline ≥ 98 percent in a prospective phase II study. Any disease with SUV over 3 is in red. Credit: Michael Hofman, John Violet, Shahneen Sandhu, Justin Ferdinandus, Amir Iravani, Grace Kong, Aravind Ravi Kumar, Tim Akhurst, Sue Ping Thang, Price Jackson, Mark Scalzo, Scott Williams and Rodney Hicks, Peter MacCallum Cancer Centre, Melbourne, Australia.

News | PET Imaging | June 29, 2018
In the battle against metastatic castrate-resistant prostate cancer, studies have demonstrated a high response rate to...
MILabs Introduces Futuristic PET Capabilities on New VECTor6 System
Technology | PET Imaging | June 28, 2018
At the 2018 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, June 23-26, in Philadelphia,...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
Overlay Init